Non-Hodgkin Lymphoma (NHL) Therapeutics Market By Type of Therapy (Immunotherapy, Targeted Therapy, Chemotherapy, Stem Cell Transplant, Others), By Cell Type (B-cell Lymphomas, T-cell Lymphomas), By Drug Type (Revlimid, Rituxan, Keytruda, Imbruvica, Opdivo, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others), By Region, Competition Forecast & Opportunities, 2020-2030F
The Global Non-Hodgkin Lymphoma (NHL) Therapeutics Market , valued at USD 8.19 Billion in 2024, is projected to experience a CAGR of 7.61% to reach USD 12.72 Billion by 2030. Non-Hodgkin Lymphoma (NHL) therapeutics comprise a range of medical treatments designed to manage and combat this diverse group of blood cancers originating within the lymphatic system. These therapies, encompassing chemotherapy, targeted therapy, immunotherapy, radiation, and stem cell transplantation, aim to eliminate malignant cells and improve patient outcomes.
Key Market Drivers
Advancements in immunotherapy and CAR T-cell therapies are a primary driver for the Non-Hodgkin Lymphoma therapeutics market, introducing highly effective and specialized treatments. These modalities utilize the patient's immune system or engineered immune cells to precisely target and eliminate cancer cells, offering transformative outcomes for aggressive or refractory NHL. Their increasing adoption, including expansion into earlier lines of treatment, significantly boosts market value. According to Gilead Sciences' full year 2024 financial results, released in February 2025, Cell Therapy product sales, encompassing NHL therapies like Yescarta, increased by 6% to reach $2.0 billion in the full year 2024 compared to 2023, reflecting substantial commercial success and clinical integration.
Key Market Challenges
The high cost associated with advanced therapeutic modalities presents a significant impediment to the growth of the Global Non-Hodgkin Lymphoma (NHL) Therapeutics Market. Modern treatments, particularly immunotherapies, often feature substantial price tags. This directly limits patient access to potentially life-saving or life-extending therapies, especially in healthcare systems with stringent budgetary controls or for individuals with inadequate insurance coverage. Even for patients with coverage, significant out-of-pocket expenses can lead to treatment delays or abandonment, compromising optimal patient outcomes.
Key Market Trends
A significant trend driving the Global Non-Hodgkin Lymphoma therapeutics market is the robust pipeline development and continuous launch of novel drugs. This trend signifies a broader expansion of therapeutic options beyond established categories, addressing diverse patient needs and resistance mechanisms. According to OncLive, almost 20 FDA approvals occurred in the hematology sphere in 2024, demonstrating consistent innovation across blood cancers. This influx of new treatments provides clinicians with more tools to manage the complex and varied subtypes of NHL, including those that are aggressive or refractory.
Key Market Players
In this report, the Global Non-Hodgkin Lymphoma (NHL) Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Company Profiles: Detailed analysis of the major companies presents in the Global Non-Hodgkin Lymphoma (NHL) Therapeutics Market .
Available Customizations:
Global Non-Hodgkin Lymphoma (NHL) Therapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
Key Market Drivers
Advancements in immunotherapy and CAR T-cell therapies are a primary driver for the Non-Hodgkin Lymphoma therapeutics market, introducing highly effective and specialized treatments. These modalities utilize the patient's immune system or engineered immune cells to precisely target and eliminate cancer cells, offering transformative outcomes for aggressive or refractory NHL. Their increasing adoption, including expansion into earlier lines of treatment, significantly boosts market value. According to Gilead Sciences' full year 2024 financial results, released in February 2025, Cell Therapy product sales, encompassing NHL therapies like Yescarta, increased by 6% to reach $2.0 billion in the full year 2024 compared to 2023, reflecting substantial commercial success and clinical integration.
Key Market Challenges
The high cost associated with advanced therapeutic modalities presents a significant impediment to the growth of the Global Non-Hodgkin Lymphoma (NHL) Therapeutics Market. Modern treatments, particularly immunotherapies, often feature substantial price tags. This directly limits patient access to potentially life-saving or life-extending therapies, especially in healthcare systems with stringent budgetary controls or for individuals with inadequate insurance coverage. Even for patients with coverage, significant out-of-pocket expenses can lead to treatment delays or abandonment, compromising optimal patient outcomes.
Key Market Trends
A significant trend driving the Global Non-Hodgkin Lymphoma therapeutics market is the robust pipeline development and continuous launch of novel drugs. This trend signifies a broader expansion of therapeutic options beyond established categories, addressing diverse patient needs and resistance mechanisms. According to OncLive, almost 20 FDA approvals occurred in the hematology sphere in 2024, demonstrating consistent innovation across blood cancers. This influx of new treatments provides clinicians with more tools to manage the complex and varied subtypes of NHL, including those that are aggressive or refractory.
Key Market Players
- AstraZeneca PLC
- Baxter International Inc.
- Bayer AG
- Novartis AG
- Eli Lilly and Company.
- Spectrum Pharmaceuticals, Inc.
- Teva Pharmaceutical Industries Ltd.
- Bristol Myers Squibb Company
- GlaxoSmithKline PLC
- Janssen Pharmaceuticals, Inc.
In this report, the Global Non-Hodgkin Lymphoma (NHL) Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
- Non-Hodgkin Lymphoma (NHL) Therapeutics Market , By Type of Therapy:
- Immunotherapy
- Targeted Therapy
- Chemotherapy
- Stem Cell Transplant
- Others
- Non-Hodgkin Lymphoma (NHL) Therapeutics Market , By Cell Type:
- B-cell Lymphomas
- T-cell Lymphomas
- Non-Hodgkin Lymphoma (NHL) Therapeutics Market , By Drug Type:
- Revlimid
- Rituxan
- Keytruda
- Imbruvica
- Opdivo
- Others
- Non-Hodgkin Lymphoma (NHL) Therapeutics Market , By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Others
- Non-Hodgkin Lymphoma (NHL) Therapeutics Market , By Region:
- North America
- United States
- Canada
- Mexico
- Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- South America
- Brazil
- Argentina
- Colombia
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
Company Profiles: Detailed analysis of the major companies presents in the Global Non-Hodgkin Lymphoma (NHL) Therapeutics Market .
Available Customizations:
Global Non-Hodgkin Lymphoma (NHL) Therapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up to five).
1. PRODUCT OVERVIEW
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. RESEARCH METHODOLOGY
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. EXECUTIVE SUMMARY
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. VOICE OF CUSTOMER
5. GLOBAL NON-HODGKIN LYMPHOMA (NHL) THERAPEUTICS MARKET OUTLOOK
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Type of Therapy (Immunotherapy, Targeted Therapy, Chemotherapy, Stem Cell Transplant, Others)
5.2.2. By Cell Type (B-cell Lymphomas, T-cell Lymphomas)
5.2.3. By Drug Type (Revlimid, Rituxan, Keytruda, Imbruvica, Opdivo, Others)
5.2.4. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others)
5.2.5. By Region
5.2.6. By Company (2024)
5.3. Market Map
6. NORTH AMERICA NON-HODGKIN LYMPHOMA (NHL) THERAPEUTICS MARKET OUTLOOK
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Type of Therapy
6.2.2. By Cell Type
6.2.3. By Drug Type
6.2.4. By Distribution Channel
6.2.5. By Country
6.3. North America: Country Analysis
6.3.1. United States Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Type of Therapy
6.3.1.2.2. By Cell Type
6.3.1.2.3. By Drug Type
6.3.1.2.4. By Distribution Channel
6.3.2. Canada Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Type of Therapy
6.3.2.2.2. By Cell Type
6.3.2.2.3. By Drug Type
6.3.2.2.4. By Distribution Channel
6.3.3. Mexico Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Type of Therapy
6.3.3.2.2. By Cell Type
6.3.3.2.3. By Drug Type
6.3.3.2.4. By Distribution Channel
7. EUROPE NON-HODGKIN LYMPHOMA (NHL) THERAPEUTICS MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Type of Therapy
7.2.2. By Cell Type
7.2.3. By Drug Type
7.2.4. By Distribution Channel
7.2.5. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Type of Therapy
7.3.1.2.2. By Cell Type
7.3.1.2.3. By Drug Type
7.3.1.2.4. By Distribution Channel
7.3.2. France Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Type of Therapy
7.3.2.2.2. By Cell Type
7.3.2.2.3. By Drug Type
7.3.2.2.4. By Distribution Channel
7.3.3. United Kingdom Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Type of Therapy
7.3.3.2.2. By Cell Type
7.3.3.2.3. By Drug Type
7.3.3.2.4. By Distribution Channel
7.3.4. Italy Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Type of Therapy
7.3.4.2.2. By Cell Type
7.3.4.2.3. By Drug Type
7.3.4.2.4. By Distribution Channel
7.3.5. Spain Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Type of Therapy
7.3.5.2.2. By Cell Type
7.3.5.2.3. By Drug Type
7.3.5.2.4. By Distribution Channel
8. ASIA PACIFIC NON-HODGKIN LYMPHOMA (NHL) THERAPEUTICS MARKET OUTLOOK
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Type of Therapy
8.2.2. By Cell Type
8.2.3. By Drug Type
8.2.4. By Distribution Channel
8.2.5. By Country
8.3. Asia Pacific: Country Analysis
8.3.1. China Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Type of Therapy
8.3.1.2.2. By Cell Type
8.3.1.2.3. By Drug Type
8.3.1.2.4. By Distribution Channel
8.3.2. India Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Type of Therapy
8.3.2.2.2. By Cell Type
8.3.2.2.3. By Drug Type
8.3.2.2.4. By Distribution Channel
8.3.3. Japan Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Type of Therapy
8.3.3.2.2. By Cell Type
8.3.3.2.3. By Drug Type
8.3.3.2.4. By Distribution Channel
8.3.4. South Korea Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Type of Therapy
8.3.4.2.2. By Cell Type
8.3.4.2.3. By Drug Type
8.3.4.2.4. By Distribution Channel
8.3.5. Australia Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Type of Therapy
8.3.5.2.2. By Cell Type
8.3.5.2.3. By Drug Type
8.3.5.2.4. By Distribution Channel
9. MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA (NHL) THERAPEUTICS MARKET OUTLOOK
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Type of Therapy
9.2.2. By Cell Type
9.2.3. By Drug Type
9.2.4. By Distribution Channel
9.2.5. By Country
9.3. Middle East & Africa: Country Analysis
9.3.1. Saudi Arabia Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Type of Therapy
9.3.1.2.2. By Cell Type
9.3.1.2.3. By Drug Type
9.3.1.2.4. By Distribution Channel
9.3.2. UAE Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Type of Therapy
9.3.2.2.2. By Cell Type
9.3.2.2.3. By Drug Type
9.3.2.2.4. By Distribution Channel
9.3.3. South Africa Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Type of Therapy
9.3.3.2.2. By Cell Type
9.3.3.2.3. By Drug Type
9.3.3.2.4. By Distribution Channel
10. SOUTH AMERICA NON-HODGKIN LYMPHOMA (NHL) THERAPEUTICS MARKET OUTLOOK
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Type of Therapy
10.2.2. By Cell Type
10.2.3. By Drug Type
10.2.4. By Distribution Channel
10.2.5. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Type of Therapy
10.3.1.2.2. By Cell Type
10.3.1.2.3. By Drug Type
10.3.1.2.4. By Distribution Channel
10.3.2. Colombia Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Type of Therapy
10.3.2.2.2. By Cell Type
10.3.2.2.3. By Drug Type
10.3.2.2.4. By Distribution Channel
10.3.3. Argentina Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Type of Therapy
10.3.3.2.2. By Cell Type
10.3.3.2.3. By Drug Type
10.3.3.2.4. By Distribution Channel
11. MARKET DYNAMICS
11.1. Drivers
11.2. Challenges
12. MARKET TRENDS & DEVELOPMENTS
12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments
13. GLOBAL NON-HODGKIN LYMPHOMA (NHL) THERAPEUTICS MARKET : SWOT ANALYSIS
14. PORTER'S FIVE FORCES ANALYSIS
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products
15. COMPETITIVE LANDSCAPE
15.1. AstraZeneca PLC
15.1.1. Business Overview
15.1.2. Products & Services
15.1.3. Recent Developments
15.1.4. Key Personnel
15.1.5. SWOT Analysis
15.2. Baxter International Inc.
15.3. Bayer AG
15.4. Novartis AG
15.5. Eli Lilly and Company.
15.6. Spectrum Pharmaceuticals, Inc.
15.7. Teva Pharmaceutical Industries Ltd.
15.8. Bristol Myers Squibb Company
15.9. GlaxoSmithKline PLC
15.10. Janssen Pharmaceuticals, Inc.
16. STRATEGIC RECOMMENDATIONS
17. ABOUT US & DISCLAIMER
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. RESEARCH METHODOLOGY
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. EXECUTIVE SUMMARY
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. VOICE OF CUSTOMER
5. GLOBAL NON-HODGKIN LYMPHOMA (NHL) THERAPEUTICS MARKET OUTLOOK
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Type of Therapy (Immunotherapy, Targeted Therapy, Chemotherapy, Stem Cell Transplant, Others)
5.2.2. By Cell Type (B-cell Lymphomas, T-cell Lymphomas)
5.2.3. By Drug Type (Revlimid, Rituxan, Keytruda, Imbruvica, Opdivo, Others)
5.2.4. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others)
5.2.5. By Region
5.2.6. By Company (2024)
5.3. Market Map
6. NORTH AMERICA NON-HODGKIN LYMPHOMA (NHL) THERAPEUTICS MARKET OUTLOOK
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Type of Therapy
6.2.2. By Cell Type
6.2.3. By Drug Type
6.2.4. By Distribution Channel
6.2.5. By Country
6.3. North America: Country Analysis
6.3.1. United States Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Type of Therapy
6.3.1.2.2. By Cell Type
6.3.1.2.3. By Drug Type
6.3.1.2.4. By Distribution Channel
6.3.2. Canada Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Type of Therapy
6.3.2.2.2. By Cell Type
6.3.2.2.3. By Drug Type
6.3.2.2.4. By Distribution Channel
6.3.3. Mexico Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Type of Therapy
6.3.3.2.2. By Cell Type
6.3.3.2.3. By Drug Type
6.3.3.2.4. By Distribution Channel
7. EUROPE NON-HODGKIN LYMPHOMA (NHL) THERAPEUTICS MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Type of Therapy
7.2.2. By Cell Type
7.2.3. By Drug Type
7.2.4. By Distribution Channel
7.2.5. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Type of Therapy
7.3.1.2.2. By Cell Type
7.3.1.2.3. By Drug Type
7.3.1.2.4. By Distribution Channel
7.3.2. France Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Type of Therapy
7.3.2.2.2. By Cell Type
7.3.2.2.3. By Drug Type
7.3.2.2.4. By Distribution Channel
7.3.3. United Kingdom Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Type of Therapy
7.3.3.2.2. By Cell Type
7.3.3.2.3. By Drug Type
7.3.3.2.4. By Distribution Channel
7.3.4. Italy Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Type of Therapy
7.3.4.2.2. By Cell Type
7.3.4.2.3. By Drug Type
7.3.4.2.4. By Distribution Channel
7.3.5. Spain Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Type of Therapy
7.3.5.2.2. By Cell Type
7.3.5.2.3. By Drug Type
7.3.5.2.4. By Distribution Channel
8. ASIA PACIFIC NON-HODGKIN LYMPHOMA (NHL) THERAPEUTICS MARKET OUTLOOK
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Type of Therapy
8.2.2. By Cell Type
8.2.3. By Drug Type
8.2.4. By Distribution Channel
8.2.5. By Country
8.3. Asia Pacific: Country Analysis
8.3.1. China Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Type of Therapy
8.3.1.2.2. By Cell Type
8.3.1.2.3. By Drug Type
8.3.1.2.4. By Distribution Channel
8.3.2. India Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Type of Therapy
8.3.2.2.2. By Cell Type
8.3.2.2.3. By Drug Type
8.3.2.2.4. By Distribution Channel
8.3.3. Japan Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Type of Therapy
8.3.3.2.2. By Cell Type
8.3.3.2.3. By Drug Type
8.3.3.2.4. By Distribution Channel
8.3.4. South Korea Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Type of Therapy
8.3.4.2.2. By Cell Type
8.3.4.2.3. By Drug Type
8.3.4.2.4. By Distribution Channel
8.3.5. Australia Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Type of Therapy
8.3.5.2.2. By Cell Type
8.3.5.2.3. By Drug Type
8.3.5.2.4. By Distribution Channel
9. MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA (NHL) THERAPEUTICS MARKET OUTLOOK
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Type of Therapy
9.2.2. By Cell Type
9.2.3. By Drug Type
9.2.4. By Distribution Channel
9.2.5. By Country
9.3. Middle East & Africa: Country Analysis
9.3.1. Saudi Arabia Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Type of Therapy
9.3.1.2.2. By Cell Type
9.3.1.2.3. By Drug Type
9.3.1.2.4. By Distribution Channel
9.3.2. UAE Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Type of Therapy
9.3.2.2.2. By Cell Type
9.3.2.2.3. By Drug Type
9.3.2.2.4. By Distribution Channel
9.3.3. South Africa Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Type of Therapy
9.3.3.2.2. By Cell Type
9.3.3.2.3. By Drug Type
9.3.3.2.4. By Distribution Channel
10. SOUTH AMERICA NON-HODGKIN LYMPHOMA (NHL) THERAPEUTICS MARKET OUTLOOK
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Type of Therapy
10.2.2. By Cell Type
10.2.3. By Drug Type
10.2.4. By Distribution Channel
10.2.5. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Type of Therapy
10.3.1.2.2. By Cell Type
10.3.1.2.3. By Drug Type
10.3.1.2.4. By Distribution Channel
10.3.2. Colombia Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Type of Therapy
10.3.2.2.2. By Cell Type
10.3.2.2.3. By Drug Type
10.3.2.2.4. By Distribution Channel
10.3.3. Argentina Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Type of Therapy
10.3.3.2.2. By Cell Type
10.3.3.2.3. By Drug Type
10.3.3.2.4. By Distribution Channel
11. MARKET DYNAMICS
11.1. Drivers
11.2. Challenges
12. MARKET TRENDS & DEVELOPMENTS
12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments
13. GLOBAL NON-HODGKIN LYMPHOMA (NHL) THERAPEUTICS MARKET : SWOT ANALYSIS
14. PORTER'S FIVE FORCES ANALYSIS
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products
15. COMPETITIVE LANDSCAPE
15.1. AstraZeneca PLC
15.1.1. Business Overview
15.1.2. Products & Services
15.1.3. Recent Developments
15.1.4. Key Personnel
15.1.5. SWOT Analysis
15.2. Baxter International Inc.
15.3. Bayer AG
15.4. Novartis AG
15.5. Eli Lilly and Company.
15.6. Spectrum Pharmaceuticals, Inc.
15.7. Teva Pharmaceutical Industries Ltd.
15.8. Bristol Myers Squibb Company
15.9. GlaxoSmithKline PLC
15.10. Janssen Pharmaceuticals, Inc.
16. STRATEGIC RECOMMENDATIONS
17. ABOUT US & DISCLAIMER
